AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00723099 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT00723099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo umbilical cord blood transplant
Study NCT02224963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive Problem-Solving Training
Description: Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
Study NCT02224963 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life and Health Review
Description: Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
Study NCT02572947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Study NCT02579798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEP (positive end-expiratory pressure)
Study NCT02579798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP (positive end-expiratory pressure)
Study NCT04110028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00525772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciclesonide
Description: low dose- 50ug and 200ug
Study NCT00525772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciclesonide
Description: high dose- 100ug and 400ug
Study NCT03962296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitis vinifera extract
Description: Three daily oral doses of 50mg tablets of Vitis vinifera extract(Entelon®, Hanlim Pharm, Seoul, South Korea) were administered to patients in this group
Study NCT03962296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Dobesilate
Description: Three daily oral doses of 50mg tablets of Calcium Dobesilate(Doxium®, Ilsung Pharm, Seoul, South Korea) were administered to patients in this group
Study NCT03962296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets lacked Vitis vinifera extract or calcium dobesilate, but their appearance was identical to those of the study group tablets.
Study NCT05680454 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
Description: For Low-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6.
Study NCT05680454 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine
Description: A 3-dose regimen administered at months 0, 2 and 6.
Study NCT00936754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules similar in aspect and weight to active product, taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
Study NCT00507429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA4P
Description: CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles
Study NCT00507429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 200mg/m squared on Day 1
Study NCT00730522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPP-109 vigabatrin
Description: tablets, bid for 12 weeks
Study NCT00730522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: tablets, bid, 12 weeks
Study NCT02391428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood test
Description: Blood test: Small volume (3 ml) of blood will be taken by venipuncture into ethylenediaminetetraacetic acid (EDTA) tube.
Study NCT02391428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega3 capsules
Description: Only ADHD children will be given a supply of omega3 capsules (containing 400 mg EPA and 200 mg DHA)
Study NCT01883089 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational Enhancement Therapy
Study NCT03692676 — intervention group
Intervention type: DEVICE
Intervention: Spiriva Respimat
Description: soft-mist inhaler
Study NCT03557138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside
Description: positron emission tomography and magnetic resonance imaging (PET/MRI) of kidneys of diabetic patients using alpha-Methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside (Me4FDG)
Study NCT00521248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms
Study NCT00507429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: 6 AUC on Day 1 following paclitaxel
Study NCT00521248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral morphine solution
Description: 0.4 mg/kg/day morphine every 4 hours
Study NCT03604120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preoxygenation with high flow therapy by nasal cannula
Description: Preoxygenation during 4 minutes with High Flow Nasal Cannula (60l/min FiO2 = 1) before fiber-optic or laryngoscopic intubation. The device will be maintained in place throughout the intubation procedure in order to achieve oxygenation.
Study NCT03604120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation by standard Facial mask
Description: * For Fiber-optic intubation: patients will receive a 4 minutes FIBROXY facial mask preoxygenation with FiO2=100%. The FIBROXY facial mask will be maintained in place during the intubation procedure.~* For Laryngoscopic intubation: patients will receive a 4 minutes standard facial mask preoxygenation with FiO2=100%. The standard facial mask will be removed after crash induction to proceed to intubation.
Study NCT04843163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NAMI Basics
Description: NAMI Basics is a peer service program for caregivers of children with mental health needs. It was created by the National Alliance on Mental Illness (NAMI) and was adapted from their empirically supported model for caregivers of adult children with mental illness (Family-to-Family). The child-focused intervention, NAMI Basics, is a six-class curriculum focused on increasing caregiver knowledge about mental illness, empowering parents to advocate for their children across service systems, and introducing skills that assist in family problem-solving and communication (Brister et al., 2012). The program is currently available widely throughout the U.S. through certified trainers who volunteer with local NAMI affiliates and is provided free of charge to caregivers in a non-stigmatizing community setting (e.g., local school, church, community center). It is open to all caregivers, regardless of mental health diagnosis or time within a treatment system.
Study NCT02324998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: PARP Inhibitor
Study NCT02324998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Gonadotrophin releasing hormone blocker
Study NCT00602914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet
Description: The micronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the skin). In this study the MicronJet will be used to inject insulin vs. a convention needle injection.
Study NCT03718455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axillary Magseed
Description: The Magseed will replace the investigators' current clinical practice of using radioactive seeds in women receiving neoadjuvant chemotherapy.
Study NCT02275923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveal LINQ™ Insertable Cardiac Monitor
Description: Insertable cardiac monitor
Study NCT00602914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet
Description: MicronJet, Intradermal Injection
Study NCT02575898 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: First Session
Description: Creative Practice and Positive Re-enforcement
Study NCT02575898 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Second Session
Description: Disease Related
Study NCT02575898 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Third through Sixth Sessions
Description: Life Review and Legacy
Study NCT01368445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine hydrochloride 0.15% Nasal Spray
Description: 1644 mcg, 2 sprays per nostril twice daily AM \& PM)
Study NCT01368445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: azelastine hydrochloride 0.15% Nasal Spray
Description: 1644 mcg, 2 sprays per nostril twice daily AM \& PM)
Study NCT01368445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine hydrochloride 0.15% and Placebo
Description: 822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
Study NCT01368445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: azelastine hydrochloride 0.15% and Placebo
Description: 822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
Study NCT01368445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine 0.1%, Nasal Spray
Description: 1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM \& PM)
Study NCT01368445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azelastine 0.1%, Nasal Spray
Description: 1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM \& PM)
Study NCT02833441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Study NCT03982043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text2Connect
Description: Text2Connect is a personalized text messaging intervention for patients and parents that targets self-identified barriers to engaging in treatment to increase the likelihood that a depressed or suicidal patient will initiate recommended services.
Study NCT03699280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Oculus Go VR device
Study NCT03430479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A
Description: Radiation + Nivolumab + hormone therapy
Study NCT01513265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaceutical care plan, mostly based on the RASP
Description: Drug use of subjects enrolled in this arm will be systematically evaluated by a clinical pharmacist, using the RASP list. Potentially inappropriate drug use will be pointed out to the treating physician. The pharmaceutical advice is not limited to the RASP list. Any actual change in drug prescription will be decided by the treating physician based upon comprehensive medical evaluations in each individual patient.
Study NCT03722758 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectrum TPH3
Description: tooth restoration with two different restorative materials
Study NCT03722758 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Riva LC
Description: tooth restoration with two different restorative materials
Study NCT03159234 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: fetal lung volume
Description: the best method for measurement of fetal lung volume is by the rotational technique in which each lung is obtained by serial contouring of the pulmonary area after rotating the volumetric image.this is more recent method seems to have advantages allowing finer contouring of the lung and subsequent modification of the contour as well as being better able to estimate the volumes of irregular and small lung as in congenital diaphragmatic hernia
Study NCT03159234 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: pulmonary artery resistance index
Description: Women placed in semirecumbent position and an axial plane through the fetal thorax to achieve 4 chamber view of the heart. The main pulmonary artery was followed to the point where it divides into right and left branches by rotating the transducer from the 4 chamber view to the short axis view of the heart. Pulsed and colour Doppler was used. The fetal pulmonary artery flow waveform measurements was taken within the proximal portion of the main pulmonary artery
Study NCT01379976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcarnitine
Description: ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal.
Study NCT01379976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal.
Study NCT01141023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaTscan
Study NCT03159234 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Fetal adrenal gland volume:
Description: the adrenal gland has a characteristic sonographic appearance; each limb is seen as a long anechoic structure with a thin, echogenic line within its center . Both limbs can sometimes be seen in the coronal plane, and if so there is a strong echogenic line between limbs (probably fat). On the basis of pathologic and histologic studies , we believe the anechoic bulk of the gland represents the fetal zone of the cortex, while the central echogenic core is the medulla.
Study NCT04064411 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: abaloparatide
Description: Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
Study NCT04064411 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide solid microstructured transdermal system
Description: Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto a sMTS array for transdermal administration of abaloparatide.
Study NCT03634995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified dose on specified days
Study NCT02746263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Study NCT02746263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral acetaminophen
Study NCT02746263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Patient controlled analgesia
Study NCT03634995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT02746263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Patient controlled analgesia
Study NCT02682342 — intervention group
Intervention type: OTHER
Intervention: 75 g glucose solution
Description: This is the same as the standard oral glucose challenge dose and route given clinically
Study NCT03543969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 450 mg encorafenib daily by mouth
Study NCT03543969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: 45 mg binimetinib daily by mouth
Study NCT02201498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomies with Formocresol/OZE and Biodentine
Study NCT02123992 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elevate Apical and Posterior
Study NCT02123992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Native Tissue Repair for pelvic organ prolapse
Study NCT00958256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m\^2 given intravenously over 3-5 seconds at the end of infusion of Rituximab on Day 1 of every cycle, then on Days 4, 8 and 11 of every cycle.
Study NCT00958256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 given intravenously over 6-8 hours on Day 1 of every 21-day study cycle.
Study NCT00958256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenously over 3 hours 2 times each day (6 hours total each day) on Days 2, 3, and 4 of every cycle
Study NCT03543969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg Nivolumab IV every 2 weeks
Study NCT00958256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 600 mg/m\^2 intravenous continuous infusion (IVCI) over 24 hours daily for 3 days, 1 hour prior to Cyclophosphamide and complete by 12 hours after last dose of Cyclophosphamide.
Study NCT00958256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 micrograms/kg subcutaneously daily starting 24-36 hours for 7 days after last dose of Bortezomib until granulocytes are more than 4 x 103/dl.
Study NCT03912207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
Study NCT03543969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: 240 mg Nivolumab IV every 2 weeks
Study NCT02051374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression alone
Study NCT02051374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression followed by fusion with instrumentation
Study NCT02243709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone 600-mg/day or placebo for a week
Description: 600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine
Study NCT02243709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mifepristone 600-mg/day or placebo for a week
Description: 600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine
Study NCT03912207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Saline is a routinely used placebo.
Study NCT04207814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological sample
Description: biological samples will be taken from the subjects included
Study NCT02097121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOTOX®
Description: Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex, formulation No. 9060X contains 100 U of Clostridium botulinum toxin Type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. The study medication was to be reconstituted with 0.9% sodium chloride (preservative-free). The 10 mL of study drug was to be administered as 20 injections each of 0.5 mL. Under direct cystoscopic visualization, injections were to be distributed evenly across the detrusor wall and spaced approximately 1 cm apart. To avoid injecting the trigone, the injections were to be at least 1 cm above the trigone. The injection needle was to be inserted approximately 2 mm into the detrusor for each injection.
Study NCT02735525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone monitoring
Description: Patients will be trained to use the smartphone and the wound surveillance app prior to discharge. Patients will use the app from home to take send digital images of their postoperative wounds and answer a short survey, all of which will be transmitted to a secure database maintained by the UW Department of Surgery and accessible only to UW-employed study personnel. These data will be evaluated by one of three vascular surgery service nurse practitioners (NPs) daily. Patients who have concerning findings either in their images or in their survey answers will be contacted for further evaluation.
Study NCT03939780 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [F18]RO-948
Description: Single radiotracer IV injection with subsequent emission scan
Study NCT02494986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other ARVs.
Study NCT03232073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod
Description: Ponesimod; Film-coated tablet; Oral use. From Day 1 to Day 14, ponesimod is gradually up-titrated until a maintenance dose of 20 mg is reached from Day 15